

## Ranibizumab versus Bevacizumab

### Bibliographie fournie lors du séminaire du Conseil d'administration de l'ANSM du 13 février 2014

IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.

**Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.**

Ophthalmology. 2012 Jul;119(7):1399-411. doi: [10.1016/j.ophtha.2012.04.015](https://doi.org/10.1016/j.ophtha.2012.04.015). Epub 2012 May 11. Erratum in: Ophthalmology. 2013 Sep;120(9):1719. Ophthalmology. 2012 Aug;119(8):1508.

---

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC; IVAN study investigators.

**Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.**

Lancet. 2013 Oct 12;382(9900):1258-67. doi: [10.1016/S0140-6736\(13\)61501-9](https://doi.org/10.1016/S0140-6736(13)61501-9). Epub 2013 Jul 19.

---

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

**Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.**

Ophthalmology. 2013 Nov;120(11):2300-9. doi: [10.1016/j.ophtha.2013.06.020](https://doi.org/10.1016/j.ophtha.2013.06.020). Epub 2013 Aug 2.

---

Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA

**A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.**

Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: [10.1136/bjophthalmol-2012-302391](https://doi.org/10.1136/bjophthalmol-2012-302391). Epub 2013 Jan 3.

---

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.

**Ranibizumab and bevacizumab for neovascular age-related macular degeneration.**

N Engl J Med. 2011 May 19;364(20):1897-908. doi: [10.1056/NEJMoa1102673](https://doi.org/10.1056/NEJMoa1102673). Epub 2011 Apr 28.

---

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

**Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.**

Ophthalmology. 2012 Jul;119(7):1388-98. doi: [10.1016/j.ophtha.2012.03.053](https://doi.org/10.1016/j.ophtha.2012.03.053). Epub 2012 May 1. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389193/>